Tango Therapeutics files $400 million at-the-market share sale program with Leerink
Tango Therapeutics filed a new prospectus supplement for up to $400 million of common stock sales through its existing at-the-market program with Leerink Partners, and ended the prior $100 million program. The filing carries $35.6 million of unsold shares forward into the new supplement, so the company can issue more shares, which would dilute existing holders.
Key points
- New prospectus supplement filed August 11, 2026 covers up to $400,000,000 of common stock sales through Leerink Partners LLC.
- About $64.4 million had been sold under the prior $100,000,000 program, leaving about $35.6 million unsold, which was carried into the new supplement.
- The prior offering has been terminated; shares will be sold under the Registration Statement, which became automatically effective upon filing.
- Goodwin Procter LLP issued a legal opinion on the new shares (Exhibit 5.1).
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.